Combinational benefit of antihistamines and remdesivir for reducing SARS-CoV-2 replication and alleviating inflammation-induced lung injury in miceSARS-CoV-2 복제를 감소시키고 마우스에서 염증 유발 폐 손상을 완화하기 위한 항히스타민제와 렘데시비르의 조합 이점Article Published on 2022-05-182022-09-11 Journal: Zoological research [Category] COVID19(2023년), SARS, 치료제, [키워드] alveolar antagonist Anti-inflammatory Anti-inflammatory therapy Antihistamine Antihistamines Antiviral antiviral drug antiviral therapy benefit caused Chinese clinical benefits Combination Combinational therapy COVID-19 COVID-19 treatment degranulation demonstrated Endothelial cell English epithelial feasible Histamine histamine receptor hyperinflammation Immune-mediated in vivo Inflammation inflammation-induced lung injury inflammatory disease initiate Injury lAbel loratadine Lung injury lung lesion lung lesions mast cell Mast cells MCs mediator mice off-label off-label use predicted Prevent prevented receptor reducing Remdesivir SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication SARS-CoV-2 spike SARS-CoV-2 spike protein Spike protein suggested suppress Treatment viral replication [DOI] 10.24272/j.issn.2095-8137.2021.469 PMC 바로가기 [Article Type] Article
Recommendations for the Outpatient Drug Treatment of Patients With COVID-19Article Published on 2022-05-132022-11-15 Journal: Deutsches Ärzteblatt international [Category] 진단, [키워드] Acetylsalicylic acid carried Clinical efficacy clinically Colchicine college concerning conducted Consensus Course COVID-19 COVID-19 outpatient COVID-19 patient dose drug drug treatment early phase Elderly patient Evidence expected family general practitioner high risk Hospitalization in vitro Infection Ivermectin off-label offered Outpatient Patient patient selection physician Prevent primary care Prophylaxis Randomized controlled trial recommendation reduced Remdesivir response to vaccination retrieved risk risk factor severe disease course systemic steroids the disease treated Treatment treatment for COVID-19 Trial with COVID-19 [DOI] 10.3238/arztebl.m2022.0203 PMC 바로가기
Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case SeriesAnti-SARS-CoV-2 단클론항체를 포함한 SARS-CoV-2 감염 혈액병 환자의 종합 치료: 단일 센터 경험 사례 시리즈Article Published on 2022-03-262022-09-11 Journal: Current Oncology [Category] MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered Analysis antibody Antibody therapy B.1.1.529 B.1.617.2 bamlanivimab benefit best Cancer case sery Casirivimab clearance clinical clinical effectiveness Combination Comprehensive coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient delta variant Diagnosis Effectiveness exacerbated experience FIVE hematologic hematologic malignancies Hematologic malignancy Hematological malignancies high risk Hospitalization Imdevimab Including knowledge lAbel less mAbs monoclonal antibodies monoclonal antibody Mortality off-label omicron Omicron variant oxygen oxygen supplementation Patient Potential receiving reduce reduced reduction in respiratory retrospective risk SARS-CoV-2 SARS-CoV-2 clearance SARS-COV-2 infection SARS-CoV-2-infected patient Sery severe acute respiratory syndrome Coronavirus shown Sotrovimab suggested Tolerability Treatment variant [DOI] 10.3390/curroncol29040188 PMC 바로가기 [Article Type] Article
The dynamics in applied COVID-19 pharmacotherapy and the influence of national guidance in The Netherlands: a quantitative and qualitative studyObservational Study Published on 2022-03-012022-10-04 Journal: European Journal of Hospital Pharmacy [Category] SARS, 임상, [키워드] Admission age analysed applied calculated collected conducted COVID-19 COVID-19 pandemic defined drug explain Guidance hospital hospitals implementation Infectious disease Local men multicentre National Netherlands Observational cohort study off-label organization and administration pandemic Patient percentage Policy practice guideline pulmonary medicine Quantitative receiving regimen specific treatment Support therapy Treatment Treatment protocol Variation Virology working [DOI] 10.1136/ejhpharm-2021-002781 PMC 바로가기 [Article Type] Observational Study
Dementia and COVID-19: A Case Report and Literature Review on Pain ManagementCase Report Published on 2022-02-042022-10-28 Journal: Pharmaceuticals [Category] COVID-19, [키워드] acute respiratory syndrome Agitation Atypical Brain cognitive Cognitive impairment complex coronavirus coronavirus disease COVID-19 delirium Dementia Deterioration died disease feasible Frame hemorrhage highest implementation Infection Italian literature lockdown measure Mild MOBID-2 Mortality Neuropsychiatric NPSs off-label Pain pain assessment pandemic patients Prevent reduced report review risk risk of death SARS-CoV-2 social isolation Symptom tele-neurorehabilitation Treatment [DOI] 10.3390/ph15020199 PMC 바로가기 [Article Type] Case Report
Assessment of novel technologies in healthcare – off-label use of drugs and the ethics of implementation and distribution of COVID-19 vaccines의료의 새로운 기술 평가 - 약물의 오프라벨 사용 및 COVID-19 백신의 구현 및 유통 윤리Editorial Published on 2021-12-202022-09-11 Journal: Einstein [Category] SARS, 치료제, [키워드] assessment COVID-19 vaccine distribution drug healthcare implementation off-label [DOI] 10.31744/einstein_journal/2021ED6840 PMC 바로가기 [Article Type] Editorial
SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injurySARS-CoV-2 유발 비만 세포 급속 탈과립은 폐포 상피 염증 및 폐 손상을 유발합니다Article Published on 2021-12-172022-09-10 Journal: Signal Transduction and Targeted Therapy [Category] Fulltext, SARS, 유전자 메커니즘, 치료제, [키워드] ACE-2 ACE2 acute lung injury administration alveolar alveolar epithelial cells binding Cell COVID-19 severity COVID-19 treatments degranulation disrupt epithelial epithelial cells humanized hyper-inflammation hypercytokinemia identifying immune immunomodulator immunomodulators induce Infectious diseases Inflammation initiate initiated Injury lAbel Lung inflammation Lung injury mast cell Mast cells MCs mechanism mediators mice Microbiology mucosa off-label off-label use prevented pro-inflammatory factor pro-inflammatory factors RBD binding reduce regulate rhesus macaques SARS-CoV-2 SARS-COV-2 infection signaling pathway tight junction tight junctions Trigger triggers [DOI] 10.1038/s41392-021-00849-0 PMC 바로가기 [Article Type] Article
Repurposing old molecules for new indications: Defining pillars of success from lessons in the pastReview article Published on 2021-12-012022-10-05 Journal: European journal of pharmacology [Category] 신약개발, [키워드] addition adopted approach attrition biological assay Biomarker Characteristics clinical evaluation clinical trial Compound recycling de novo defined develop Diseases drug Drug repurposing Drug rescue Effects Efficacy element Evidence Extended profiling Formulation identify include indication indications key factor knowledge lack Market exclusivity methodology observation off-label overcome pharmacological Regulatory Repositioning model repurposing resources robust therapeutic utility timelines translational [DOI] 10.1016/j.ejphar.2021.174569 [Article Type] Review article
Rapid analysis of local data to inform off-label tocilizumab use early in the COVID-19 pandemicCOVID-19 전염병 초기에 오프라벨 토실리주맙 사용을 알리기 위한 현지 데이터의 신속한 분석Randomized Controlled Trial Published on 2021-12-012022-09-12 Journal: Healthcare (Amsterdam, Netherlands) [Category] SARS, 임상, 진단, [키워드] absence Algorithm Analysis clinical benefit Clinical outcome coronavirus disease COVID-19 COVID-19 pandemic COVID-19 patient Cytokine release syndrome disseminate Evidence-based decision-making hospitalized COVID-19 patient hyperinflammatory state interleukin 6 interleukin 6 (IL-6) interleukin-6 receptor Local observational study off-label pandemic performed randomized clinical trial Rapid SARS-CoV-2 suggested Tocilizumab treated Treatment [DOI] 10.1016/j.hjdsi.2021.100581 PMC 바로가기 [Article Type] Randomized Controlled Trial
Comparison of Interleukin-6 Plasma Concentration in Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Pediatric SepsisPediatrics Published on 2021-11-152022-10-31 Journal: Frontiers in Pediatrics [Category] COVID-19, [키워드] Admission analyzed both groups CDC criteria children children with MIS-C Clinical outcome clinical outcomes collected data Concentration COVID-19 Critically ill CRP datasets demographics described diagnosed Diagnosis difference driven by dysregulated immune response elevated excluded female IL-6 IL-6 inhibitor IL-6 level immunodeficiency immunosuppressive individual inflammatory biomarkers intensive care Interleukin-6 (IL-6) International Mechanical MIS-C Mortality much lower no difference no significant difference off-label Older Patient patient data PCT plasma plasma concentration Primary outcome procalcitonin Protein question retrospective cohort study SARS-CoV-2 SARS-COV-2 infection Sepsis septic Septic shock Sex Shock significantly higher Standard therapy statistically subgroup analysis therapy thought Vasoactive Ventilation was done [DOI] 10.3389/fped.2021.756083 PMC 바로가기 [Article Type] Pediatrics